Tertiary lymphoid structures improve immunotherapy and survival in melanoma
暂无分享,去创建一个
D. Schadendorf | H. Olsson | J. Wargo | S. Warren | Rita Cabrita | M. Lauss | Adriana Sanna | M. Donia | Mathilde Skaarup Larsen | Shamik Mitra | I. Johansson | Bengt Phung | K. Harbst | J. Vallon-Christersson | Alison Schoiack | K. Lövgren | K. Jirström | K. Pietras | C. Ingvar | K. Isaksson | H. Schmidt | L. Bastholt | A. Carneiro | I. Svane | G. Jönsson | Kristina Lövgren
[1] Qiaofei Liu,et al. Circular RNA and tumor microenvironment , 2020, Cancer Cell International.
[2] K. Messer,et al. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer , 2020, Journal of Translational Medicine.
[3] E. Jaffee,et al. Effects of B cell-activating factor on tumor immunity. , 2020, JCI insight.
[4] S. Markovic,et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy , 2020, Journal of experimental & clinical cancer research : CR.
[5] C. Sautès-Fridman,et al. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies , 2020, Frontiers in Immunology.
[6] J. Wargo,et al. B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.
[7] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.
[8] C. Sautès-Fridman,et al. Tertiary lymphoid structures in the era of cancer immunotherapy , 2019, Nature Reviews Cancer.
[9] J. Madore,et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.
[10] Monika S. Kowalczyk,et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade , 2018, Cell.
[11] Paul J. Hoover,et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.
[12] J. Lunceford,et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.
[13] Merrick I Ross,et al. Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma , 2018, Nature Medicine.
[14] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[15] S. Tangye,et al. CCR6 Defines Memory B Cell Precursors in Mouse and Human Germinal Centers, Revealing Light‐Zone Location and Predominant Low Antigen Affinity , 2017, Immunity.
[16] M. Ringnér,et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma , 2017, Nature Communications.
[17] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[18] L. Saal,et al. NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics , 2017, Molecular oncology.
[19] P. A. Futreal,et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.
[20] Suan Dan,et al. マウスおよびヒトはい中心におけるCCR6は記憶B細胞前駆体,光帯を明らかにする位置と主要な低抗原親和性【Powered by NICT】 , 2017 .
[21] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[22] Jeffrey T Leek,et al. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown , 2016, Nature Protocols.
[23] Charles H. Yoon,et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.
[24] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[25] M. Mihm,et al. Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response , 2015, Cancer Immunology Research.
[26] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[27] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[28] Pornpimol Charoentong,et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.
[29] S. Gnjatic,et al. Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity , 2015, Front. Immunol..
[30] U. Klein,et al. Dynamics of B cells in germinal centres , 2015, Nature Reviews Immunology.
[31] C. Sautès-Fridman,et al. Tertiary lymphoid structures in cancer and beyond. , 2014, Trends in immunology.
[32] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[33] Albert Kriegner,et al. Monitoring of Technical Variation in Quantitative High-Throughput Datasets , 2013, Cancer informatics.
[34] Alfonso Valencia,et al. APPRIS: annotation of principal and alternative splice isoforms , 2012, Nucleic Acids Res..
[35] V. Sondak,et al. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.
[36] J. J. van den Oord,et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. , 2012, Cancer research.
[37] M. Ringnér,et al. Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma , 2012, Clinical Cancer Research.
[38] Jason Li,et al. CONTRA: copy number analysis for targeted resequencing , 2012, Bioinform..
[39] J. Tímár,et al. Prognostic impact of B-cell density in cutaneous melanoma , 2011, Cancer Immunology, Immunotherapy.
[40] Emmanuel Barillot,et al. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..
[41] K. Tarte,et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. , 2003, Blood.
[42] P. Rogers,et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. , 2001, Immunity.
[43] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.